These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 21879782)

  • 1. Communication in drug safety: a report from an interactive debate held at the 10th annual meeting of the international society of pharmacovigilance (ISoP), 2010.
    Bahri P; Mol PG; Théophile H; Edwards IR; Hugman BP
    Drug Saf; 2011 Oct; 34(10):881-2. PubMed ID: 21879782
    [No Abstract]   [Full Text] [Related]  

  • 2. The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance.
    Bahri P; Dodoo AN; Edwards BD; Edwards IR; Fermont I; Hagemann U; Hartigan-Go K; Hugman B; Mol PG
    Drug Saf; 2015 Jul; 38(7):621-7. PubMed ID: 26032946
    [No Abstract]   [Full Text] [Related]  

  • 3. The role and strategy of ISoP in global pharmacovigilance.
    Olsson S; Harrison-Woolrych M
    Int J Clin Pharm; 2018 Aug; 40(4):740-743. PubMed ID: 30073610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The International Society of Pharmacovigilance (ISoP) Pharmacogenomic Special Interest Group: Pharmacogenomics in Pharmacovigilance.
    Yue QY
    Drug Saf; 2021 Jun; 44(6):615-617. PubMed ID: 33964001
    [No Abstract]   [Full Text] [Related]  

  • 5. The International Society of Pharmacovigilance (ISoP) Special Interest Group on Herbal and Traditional Medicines: Towards Progress in Pharmacovigilance for Herbal and Traditional Medicines and Other "Natural Health" Products.
    Barnes J
    Drug Saf; 2020 Jul; 43(7):619-622. PubMed ID: 32328906
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacovigilance--Current and Future Challenges. Abstracts of the International Society of Pharmacovigilance annual conference. Dublin, Ireland, 6-8 October 2004.
    Drug Saf; 2004; 27(12):911-77. PubMed ID: 15988859
    [No Abstract]   [Full Text] [Related]  

  • 7. [Adverse drug reaction - Definitions, risk factors and pharmacovigilance].
    Krähenbühl S
    Ther Umsch; 2015 Dec; 72(11-12):669-71. PubMed ID: 26654809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance.
    Zink RC; Huang Q; Zhang LY; Bao WJ
    Chin J Nat Med; 2013 May; 11(3):314-20. PubMed ID: 23725848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obstacles to transparency over pharmacovigilance data within the EMA.
    Prescrire Int; 2015 Nov; 24(165):278-9. PubMed ID: 26688911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of pharmacovigilance on drug portfolio management.
    Bucurescu S
    Eur Rev Med Pharmacol Sci; 2014; 18(15):2237-9. PubMed ID: 25070831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug safety. Why and how? "All drugs are dangerous, some are also useful"].
    Moore N
    Prog Urol; 2013 Nov; 23(15):1213-5. PubMed ID: 24183077
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacovigilance and use of online health information.
    Masoni M; Guelfi MR; Conti A; Gensini GF
    Trends Pharmacol Sci; 2013 Jul; 34(7):357-8. PubMed ID: 23759353
    [No Abstract]   [Full Text] [Related]  

  • 14. Adverse drug reactions in neonates: could we be documenting more?
    Hawcutt DB; O'Connor O; Turner MA
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):807-20. PubMed ID: 25225053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementing a medication safety and poison prevention program at a senior center.
    Gershman JA
    Consult Pharm; 2013 Oct; 28(10):670-1. PubMed ID: 24129222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.
    Awada Z; Zgheib NK
    Pharmacogenomics; 2014 Apr; 15(6):845-56. PubMed ID: 24897290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Physician attitudes toward the reporting of adverse drug reactions on the Pomeranian region].
    Schetz D; Sein Anand J
    Przegl Lek; 2015; 72(9):475-8. PubMed ID: 26827571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of a regional pharmacovigilance network on notification of adverse drug reactions: results at 3 years].
    Picard S; Polard E; Oger E; Bellissant E
    Therapie; 2015; 70(3):293-9. PubMed ID: 25534522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EUROmediCAT Recommendations for European Pharmacovigilance concerning safety of medication use in pregnancy.
    EUROmediCAT Steering Group
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24 Suppl 2():3-7. PubMed ID: 26395593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.